Xu Wei-Yuan, Tang Wei-Liang, Yuan Min, Sun Yong, Xu Feng, Peng Fang
Department of Cardiology, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, Zhejiang 312000, China.
Comb Chem High Throughput Screen. 2018;21(10):725-733. doi: 10.2174/1386207322666190129113448.
Circulating endothelial progenitor cells (EPCs) have regenerative capacities and play an important role in vessel wall homeostasis. When attracted to the site of vessel wall injury, EPCs rapidly differentiate into a functional layer as part of the healing process. The Genous TM endothelial progenitor cell (EPC) capturing stent is coated with anti-human CD34+ antibodies which combine with circulating EPCs from the peripheral blood to the stent surface.
This meta-analysis aims to explore the Genous TM endothelial progenitor cell capturing stent in coronary artery disease (CAD) adverse event rate after one-year follow-up.
PubMed, EMBASE and, Google Scholar databases were searched for eligible studies. CAD survival data and clinicopathological features were analyzed by expected shortfall (ES) and 95% CI. Fixed-effect model and random-effect model are used for summary statistics.
12 studies, including 15985 coronary artery disease (CAD) patients who received PCI treatment were included in this study. After 1-year follow-up, the rate of adverse event showed that the target vessel failure (TVF) was 8.5% (7.6%-17.4%), target vessel revascularization was 4.1% (TVR, 0-15.6%), target lesion revascularization was 4.2% (TLR, 3.7%-22%), myocardial infarction was 2.0% (MI, 1.8%-5.2%), major adverse cardiac events was 8.7% (MACE, 6.4%-28%), and the all-cause death was 4.0% (0-9.2).
After one-year follow-up, the incidence rate of Genous stent adverse events was stable in CAD patients. The study showed a better evaluation of Genous stent, and it provides a better reference for CAD clinical treatment.
循环内皮祖细胞（EPCs）具有再生能力，在血管壁稳态中起重要作用。当被吸引到血管壁损伤部位时，EPCs会迅速分化为功能层，作为愈合过程的一部分。Genous TM内皮祖细胞（EPC）捕获支架涂有抗人CD34 +抗体，可将外周血中的循环EPCs结合到支架表面。
本荟萃分析旨在探讨Genous TM内皮祖细胞捕获支架在冠状动脉疾病（CAD）患者一年随访后的不良事件发生率。
检索PubMed、EMBASE和谷歌学术数据库以获取符合条件的研究。通过预期短缺（ES）和95%置信区间分析CAD生存数据和临床病理特征。采用固定效应模型和随机效应模型进行汇总统计。
本研究纳入了12项研究，包括15985例接受PCI治疗的冠状动脉疾病（CAD）患者。随访1年后，不良事件发生率显示，靶血管失败（TVF）为8.5%（7.6%-17.4%），靶血管血运重建为4.1%（TVR，0-15.6%），靶病变血运重建为4.2%（TLR，3.7%-22%），心肌梗死为2.0%（MI，1.8%-5.2%），主要不良心脏事件为8.7%（MACE，6.4%-28%），全因死亡为4.0%（0-9.2）。
随访一年后，Genous支架在CAD患者中的不良事件发生率稳定。该研究对Genous支架进行了更好的评估，为CAD临床治疗提供了更好的参考。
